Testing a Primary and a Secondary Endpoint in a Group Sequential Design

被引:53
作者
Tamhane, Ajit C. [1 ]
Mehta, Cyrus R. [2 ,3 ]
Liu, Lingyun [3 ]
机构
[1] Northwestern Univ, Dept Ind Engn & Management Sci, Evanston, IL 60208 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02139 USA
[3] Cytel Corp, Cambridge, MA 02139 USA
关键词
Familywise error rate; Gatekeeping procedures; Multiple comparisons; Multiple endpoints; O'Brien-Fleming boundary; Pocock boundary; Primary power; Secondary power; CLINICAL-TRIALS; BOUNDARIES; PARAMETER;
D O I
10.1111/j.1541-0420.2010.01402.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
P>We consider a clinical trial with a primary and a secondary endpoint where the secondary endpoint is tested only if the primary endpoint is significant. The trial uses a group sequential procedure with two stages. The familywise error rate (FWER) of falsely concluding significance on either endpoint is to be controlled at a nominal level alpha. The type I error rate for the primary endpoint is controlled by choosing any alpha-level stopping boundary, e.g., the standard O'Brien-Fleming or the Pocock boundary. Given any particular alpha-level boundary for the primary endpoint, we study the problem of determining the boundary for the secondary endpoint to control the FWER. We study this FWER analytically and numerically and find that it is maximized when the correlation coefficient between the two endpoints equals 1. For the four combinations consisting of O'Brien-Fleming and Pocock boundaries for the primary and secondary endpoints, the critical constants required to control the FWER are computed for different values of . An ad hoc boundary is proposed for the secondary endpoint to address a practical concern that may be at issue in some applications. Numerical studies indicate that the O'Brien-Fleming boundary for the primary endpoint and the Pocock boundary for the secondary endpoint generally gives the best primary as well as secondary power performance. The Pocock boundary may be replaced by the ad hoc boundary for the secondary endpoint with a very little loss of secondary power if the practical concern is at issue. A clinical trial example is given to illustrate the methods.
引用
收藏
页码:1174 / 1184
页数:11
相关论文
共 15 条
[1]   P-VALUES MAXIMIZED OVER A CONFIDENCE SET FOR THE NUISANCE PARAMETER [J].
BERGER, RL ;
BOOS, DD .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1994, 89 (427) :1012-1016
[2]  
Dmitrienko A., 2010, MULTIPLE TESTING PRO
[3]   Gatekekeeping procedures with clinical trial applications [J].
Dmitrienko, Alex ;
Tamhane, Ajit C. .
PHARMACEUTICAL STATISTICS, 2007, 6 (03) :171-180
[4]   Hierarchical testing of multiple endpoints in group-sequential trials [J].
Glimm, Ekkehard ;
Maurer, Willi ;
Bretz, Frank .
STATISTICS IN MEDICINE, 2010, 29 (02) :219-228
[5]   Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials [J].
Hung, H. M. James ;
Wang, Sue-Jane ;
O'Neill, Robert .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2007, 17 (06) :1201-1210
[6]   GROUP SEQUENTIAL-TESTS FOR BIVARIATE RESPONSE - INTERIM ANALYSES OF CLINICAL-TRIALS WITH BOTH EFFICACY AND SAFETY END-POINTS [J].
JENNISON, C ;
TURNBULL, BW .
BIOMETRICS, 1993, 49 (03) :741-752
[7]  
Jennison C., 1999, GROUP SEQUENTIAL MET
[8]   DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL-TRIALS [J].
LAN, KKG ;
DEMETS, DL .
BIOMETRIKA, 1983, 70 (03) :659-663
[9]  
MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.2307/2335748
[10]   MULTIPLE TESTING PROCEDURE FOR CLINICAL-TRIALS [J].
OBRIEN, PC ;
FLEMING, TR .
BIOMETRICS, 1979, 35 (03) :549-556